{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:30:57Z","timestamp":1784140257394,"version":"3.55.0"},"reference-count":27,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25072","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T22:08:31Z","timestamp":1766527711000},"page":"268-275","source":"Crossref","is-referenced-by-count":4,"title":["CRS and ICANS in CAR T-cell therapy for large B-cell lymphoma"],"prefix":"10.3960","volume":"65","author":[{"given":"Hideki","family":"Goto","sequence":"first","affiliation":[{"name":"Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Goto H, Onozawa M, Teshima T. Novel CAR T cell therapies for patients with large B cell lymphoma. Int J Hematol. 2024; 120: 6-14.","DOI":"10.1007\/s12185-024-03792-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Xiao X, Huang S, Chen S et al.<\/i> Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021; 40: 367.","DOI":"10.1186\/s13046-021-02148-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022; 22: 85-96.","DOI":"10.1038\/s41577-021-00547-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Lee DW, Santomasso BD, Locke FL et al.<\/i> ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019; 25: 625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Juluri KR, Wu QV, Voutsinas J et al.<\/i> Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2022; 6: 2055-2068.","DOI":"10.1182\/bloodadvances.2020004142"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Schuster SJ, Tam CS, Borchmann P et al.<\/i> Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22: 1403-1415.","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Locke FL, Ghobadi A, Jacobson CA et al.<\/i> Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019; 20: 31-42.","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Abramson JS, Palomba ML, Gordon LI et al.<\/i> Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396: 839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Locke FL, Miklos DB, Jacobson CA et al.<\/i> Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022; 386: 640-654.","DOI":"10.1056\/NEJMoa2116133"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Kamdar M, Solomon SR, Arnason J et al.<\/i> Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022; 399: 2294-2308.","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Sehgal A, Hoda D, Riedell PA et al.<\/i> Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022; 23: 1066-1077.","DOI":"10.1016\/S1470-2045(22)00339-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Lee DW, Gardner R, Porter DL et al.<\/i> Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124: 188-195.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Landsburg DJ, Frigault MJ, Heim M et al.<\/i> Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. J Immunother Cancer. 2025; 13: e009890.","DOI":"10.1136\/jitc-2024-009890"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Pasquini MC, Hu ZH, Curran K et al.<\/i> Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020; 4: 5414-5424.","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Goto H, Kitawaki T, Fujii N et al.<\/i> Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan. Int J Clin Oncol. 2023; 28: 816-826.","DOI":"10.1007\/s10147-023-02334-w"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Nastoupil LJ, Jain MD, Feng L et al.<\/i> Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020; 38: 3119-3128.","DOI":"10.1200\/JCO.19.02104"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Jacobson CA, Locke FL, Ma L et al.<\/i> Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. Transplant Cell Ther. 2022; 28: 581.e1-581.e8.","DOI":"10.1016\/j.jtct.2022.05.026"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Bethge WA, Martus P, Schmitt M et al.<\/i> GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022; 140: 349-358.","DOI":"10.1182\/blood.2021015209"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Looka A, Qualls DA, Matthews D et al.<\/i> A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma. Blood Adv. 2025; 9: 455-462.","DOI":"10.1182\/bloodadvances.2024012992"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Portuguese AJ, Huang JJ, Jeon Y et al.<\/i> Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up. Haematologica. 2025; 110: 2040-2054.","DOI":"10.3324\/haematol.2024.287010"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Sesques P, Kirkwood AA, Kwon M et al.<\/i> Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J Hematol Oncol. 2024; 17: 61.","DOI":"10.1186\/s13045-024-01579-w"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Wakabayashi H, Terakura S, Ishigiwa K et al.<\/i> Simple and early prediction of severe CAR-T-related adverse events after Axi-cel infusion by initial high fever. Int J Hematol. 2025; 122: 106-116.","DOI":"10.1007\/s12185-025-03957-7"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Faramand R, Jain M, Staedtke V et al.<\/i> Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020; 26: 4823-4831.","DOI":"10.1158\/1078-0432.CCR-20-1434"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Filosto S, Vardhanabhuti S, Canales MA et al.<\/i> Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7). Blood Cancer Discov. 2024; 5: 21-33.","DOI":"10.1158\/2643-3230.BCD-23-0112"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Hayden PJ, Roddie C, Bader P et al.<\/i> Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022; 33: 259-275.","DOI":"10.1016\/j.annonc.2021.12.003"},{"key":"26","unstructured":"26 National Comprehensive Cancer Network Guidelines (NCCN). Management of CAR T-Cell and Lymphocyte Engager-Related Toxicities Version 1.2026. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1547. Accessed September 30, 2025."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023; 141: 2430-2442.","DOI":"10.1182\/blood.2022017414"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25072\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T04:41:54Z","timestamp":1766810514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25072\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25072","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25072"}}